Cala Health's Innovative kIQ System Named Best New Neurology Technology in 2026 MedTech Breakthrough Awards
In an impressive recognition of innovation in the medical technology realm, Cala Health has clinched the coveted title of 'Best New Neurology Technology Solution' at the 2026 MedTech Breakthrough Awards for its groundbreaking kIQ® System. This award signifies more than just a win; it illustrates the hard work and dedication led by Cala Health in addressing critical health challenges faced by patients with Essential Tremor (ET).
The significance of the Cala kIQ System, which is built on an advanced bioelectronic technology platform, cannot be overstated. Patients with essential tremor often experience debilitating hand and arm shaking, making simple daily tasks increasingly difficult. Traditionally, treatment options available were either invasive or insufficient, leaving many individuals seeking alternative solutions. Recognizing this gap, Cala Health has pioneered a non-invasive and easy-to-use wearable neuromodulation device designed to offer effective, at-home therapy.
The kIQ System utilizes TAPS (transcutaneous afferent patterned stimulation) therapy, whereby patients can experience relief from tremors via a wrist-worn device that requires a physician's prescription. This innovation exemplifies Cala Health's mission to enhance patient care in neurology by providing accessible and effective therapeutic solutions. According to Cala's CEO, Deanna Harshbarger, this recognition by the MedTech Breakthrough Awards is a testament to the collective effort of the team in making such a revolutionary therapy available to patients.
Essential tremor is a condition that affects over seven million individuals in the United States alone, and with limited non-invasive treatment options available, the implementation of the kIQ system marks a significant leap forward in the management of this disorder. The product's unique design allows users to incorporate the therapy seamlessly into their lives without the need for complicated medical procedures.
As competition for the 2026 MedTech Breakthrough Awards was intense, with over 5,000 nominations worldwide, Cala Health’s victory places it among other respected companies like Medtronic and CVS Health. This accolade not only solidifies Cala Health's place in the neurological treatment market but also offers hope to many patients who have been in search of effective yet non-invasive therapeutic options for their conditions.
In summary, Cala Health's kIQ System is more than just a product; it represents a paradigm shift in how essential tremor patients can approach their daily struggles with tremor. The recognition received from the MedTech Breakthrough Awards emphasizes the urgency and necessity for advancements in neurologic care, which Cala Health continues to champion through innovation. Patients are encouraged to explore how Cala Health is reshaping neurology care by visiting the company’s official website and learning about the potential benefits of the Cala kIQ System.
The significance of the Cala kIQ System, which is built on an advanced bioelectronic technology platform, cannot be overstated. Patients with essential tremor often experience debilitating hand and arm shaking, making simple daily tasks increasingly difficult. Traditionally, treatment options available were either invasive or insufficient, leaving many individuals seeking alternative solutions. Recognizing this gap, Cala Health has pioneered a non-invasive and easy-to-use wearable neuromodulation device designed to offer effective, at-home therapy.
The kIQ System utilizes TAPS (transcutaneous afferent patterned stimulation) therapy, whereby patients can experience relief from tremors via a wrist-worn device that requires a physician's prescription. This innovation exemplifies Cala Health's mission to enhance patient care in neurology by providing accessible and effective therapeutic solutions. According to Cala's CEO, Deanna Harshbarger, this recognition by the MedTech Breakthrough Awards is a testament to the collective effort of the team in making such a revolutionary therapy available to patients.
Essential tremor is a condition that affects over seven million individuals in the United States alone, and with limited non-invasive treatment options available, the implementation of the kIQ system marks a significant leap forward in the management of this disorder. The product's unique design allows users to incorporate the therapy seamlessly into their lives without the need for complicated medical procedures.
As competition for the 2026 MedTech Breakthrough Awards was intense, with over 5,000 nominations worldwide, Cala Health’s victory places it among other respected companies like Medtronic and CVS Health. This accolade not only solidifies Cala Health's place in the neurological treatment market but also offers hope to many patients who have been in search of effective yet non-invasive therapeutic options for their conditions.
In summary, Cala Health's kIQ System is more than just a product; it represents a paradigm shift in how essential tremor patients can approach their daily struggles with tremor. The recognition received from the MedTech Breakthrough Awards emphasizes the urgency and necessity for advancements in neurologic care, which Cala Health continues to champion through innovation. Patients are encouraged to explore how Cala Health is reshaping neurology care by visiting the company’s official website and learning about the potential benefits of the Cala kIQ System.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.